Drug
Panobinostat Nanoparticle Formulation MTX110 clinical trials
Also written MTX-110.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2020 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 2
The University of Texas Health Science Center, Houston (1) · Sabine Mueller, MD, PhD (1) · Biodexa Pharmaceuticals (1)
Often tested with
Tested in the same studies.
Therapeutic Procedure (1) · Complementary or Alternative Medical Procedure (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Panobinostat Nanoparticle Formulation MTX110 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults with Recurrent MedulloblastomaCompletedEarly Phase 1The University of Texas Health Science Center, HoustonNCT04315064Written as Treatment with MTX110
- A Study of Intra-tumoral Administered MTX110 in Patients With Recurrent GlioblastomaTerminatedPhase 1Biodexa PharmaceuticalsNCT05324501Written as MTX110
- MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine GliomaCompletedPhase 1/2Sabine Mueller, MD, PhDNCT03566199Written as Panobinostat Nanoparticle Formulation MTX110